CMS’ proposal not to establish payments for newly created codes for multi-analyte assays that rely on algorithmic analysis is attracting a strong rebuke from diagnostic industry and lab stakeholders.
AdvaMedDx, the American Clinical Laboratory Association (ACLA) and Biotechnology Industry Organization (BIO) each pressed CMS in recent comments to withdraw its proposal and issue final payment decisions that considers the value of these tests
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?